Please click here for more information
The European injectable drug delivery market was valued at $6.8 billion in 2012, and is expected to reach $12.4 billion by 2017 at a CAGR of 12.7% from 2012 to 2017. Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and development of nanotechnologies. In addition, the market is segmented on the basis of its therapeutic applications. In the therapeutic field, hormonal disorders command the major segment due to the high demand of injectable in the treatment of diabetes.
The growth of the injectable drug delivery technologies market is primarily triggered by favorable reimbursement policies on injectable drugs and devices, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes in Europe, and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as Spain, Russia, Denmark, Ireland and others. However, factors such as needle-stick injuries and infections and development of alternate delivery methods are restraining the growth of the market.
Germany accounted for the largest market share of the European injectable drug delivery market in 2012, followed by France. While Germany is a mature market experiencing a surge in biologics and high incidence of chronic diseases, France is the fastest-growing region. This is due to high insurance coverage for injectable devices and formulations, affordability for healthcare expenses, and activities such as exhibitions and conferences hosted by France that address injectable drug delivery technologies. The other European regions of Spain, Italy and Russia show high export potential for plastic syringes and needle, rising support for generics market, and increasing expenditure in the healthcare sector. The regions of Switzerland, Denmark, Ireland, Greece, Hungary, the Netherlands, Poland, Portugal, Romania, and Ukraine provide benefits such as favorable environment for research and development, growth in diabetic expenditures, and favorable reimbursement policies for injectable devices.
The key players in this market are Becton Dickinson & Co. (U.S.), Baxter International, Inc. (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Eli Lily & Co. (U.S.), Gerresheimer AG (Germany), Sanofi (France), West Pharmaceutical Services, Inc. (U.S.), Haselmeier GmbH (Germany), and Owen Mumford, Ltd. (U.K.).
Scope of the Report
This research report categorizes the European injectable drug delivery technologies market into two segments, namely, Europe injectable drug delivery devices technologies and European injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (Germany, France, U.K., Spain, Italy, Russia and Rest of Europe (RoE)) to provide in-depth information on the European scenario.
Europe Injectable Drug Delivery Technologies Market, By Segment
Injectable Drug Delivery Devices Technologies
Injectable Drug Delivery Formulations Technologies
Europe Injectable Drug Delivery Devices Technologies Market, By Product
Conventional Injection Devices
By Materials
Glass
Plastics
By Products
Fillable Syringes
Prefilled Syringes
By Usability
Reusable
Disposable
Self-Injection Devices
Needle Free Injectors
By Product
Fillable Syringes
Prefilled Syringes
By Technology
Jet-based Needle Free Injectors
Spring-based Needle Free Injectors
Laser Powered Needle Free Injectors
Others
By Usability
Reusable
Disposable
Auto Injectors
By Products
Fillable Syringes
Prefilled Syringes
By Technology
Manual Injection Auto Injectors
Automated Injection Auto Injectors
By Design
Standardized Auto Injectors
Customized Auto Injectors
By Usability
Reusable
Disposable
Pen Injectors
By Products
Single Chambered Pen Injectors
Dual Chambered Pen Injectors
By design
Standardized pen injectors
Customized pen injectors
By usability
Reusable
Disposable
Others (blunt-needle, micro needle, and nano needle injections)
Europe Injectable Drug Delivery Formulations Technologies, By Product
Conventional Drug Delivery Formulations
Solution
Reconstituted / Lyophilized Formulations
Novel Drug Delivery Formulations
Liposomal Systems
Microspheres
Nanoparticles
Polymeric Micelles
Others (dendrimers, nanosponge, and nanoemulsions)
Europe Injectable Drug Delivery Technologies Market, By Therapeutic Applications
Auto-immune Diseases
Multiple Sclerosis
Rheumatoid Arthritis
Crohn's Diseases
Psoriasis
Others
Hormonal Disorders
Diabetes
Antithrombotic/Thrombolytic Therapy
Reproductive Health Diseases
Anemia
Osteoporosis
Others
Orphan Diseases
Oncology
Others
Pain Management
Allergies
Hepatitis C
Aesthetic Treatment
Europe Injectable Drug Delivery Technologies Market, By Geography
Germany
France
U.K.
Spain
Italy
Russia
Rest of Europe
Help employers find you! Check out all the jobs and post your resume.
